CPRC
BSX icon

Consolidated Portfolio Review Corp’s Boston Scientific BSX Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,923
Closed -$285K – 92
2025
Q3 		$285K Sell
2,923
-213
-7% -$22.1K 0.04% 381
2025
Q2 		$337K Buy
+3,136
New +$317K 0.05% 329

Other funds holding BSX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Consolidated Portfolio Review Corp's BSX Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 2,923 shares — an estimated $285K sold.

Consolidated Portfolio Review Corp first reported a position in BSX in Q2 2025 and held it in 2 quarters. The position peaked at $337K in Q2 2025. 1,784 funds tracked by Wall St. Rank hold BSX as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 2,923 Boston Scientific shares in Q4 2025, an estimated $285K.
  • Consolidated Portfolio Review Corp first reported a position in Boston Scientific in Q2 2025 and held it in 2 quarters.
  • Consolidated Portfolio Review Corp's Boston Scientific position peaked at $337K in Q2 2025.
  • 1,784 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.